Fig. 5. Lenvatinib is more effective than anti-VEGFR2 DC101 in sensitizing gemcitabine-induced apoptosis. MCA/129 fibrosarcomas were implanted into the flank of sv129BL/6 mice. When tumors reached an average of 100mm^3, animals were treated with DC101 or increasing doses of lenvatinib 1h before a single 240 mg/kg dose of gemcitabine. Tumors were harvested at 4h after gemcitabine treatment, the time of maximal endothelial damage, and double-stained with TUNEL for apoptosis and Meca32 for endothelial cells (ECs). Data (mean±95% Cl) are collated from 4-6 mice/group. Results show lenvatinib is more effective than DC101 in enhancing ASMase-dependent endothelial apoptosis.